• 1
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 1029
  • 2
    Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009; 373: 11191132
  • 3
    Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125134
  • 4
    Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115124
  • 5
    Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345: 16551659
  • 6
    Mickisch GHJ, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001; 358: 966970
  • 7
    Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004; 171: 10711076
  • 8
    Choueiri TK, Xie W, Kollmannsberger C et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol 2011; 185: 6066
  • 9
    Kassouf W, Sanchez-Ortiz R, Tamboli P et al. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology. J Urol 2007; 178: 18961900
  • 10
    Polcari AJ, Gorbonos A, Milner JE, Flanigan RC. The role of cytoreductive nephrectomy in the era of molecular targeted therapy. Int J Urol 2009; 16: 227233
  • 11
    Surveillance, Epidemiology, and End Results (SEER) Program ( ) Research Data (1973–2009), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2012, based on the November 2011 submission
  • 12
    Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 11411154
  • 13
    Fine JP, Gray RJ. A proportional hazards model for the sub distribution of a competing risk. J Am Stat Assoc 1999; 94: 496509
  • 14
    Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 2007; 40: 381387
  • 15
    Jeldres C, Baillargeon-Gagne S, Liberman D et al. A population-based analysis of the rate of cytoreductive nephrectomy for metastatic renal cell carcinoma in the United States. Urology 2009; 74: 837841
  • 16
    Iezzoni LI, Ngo LH, Li D, Roetzheim RG, Drews RE, McCarthy EP. Early stage breast cancer treatments for younger Medicare beneficiaries with different disabilities. Health Serv Res 2008; 43 (5 Pt 1): 17521767
  • 17
    Williams S, Hakami AA, Ghavamian R et al. Outcomes with nephrectomy for metastatic kidney cancer in the era of targeted therapy. J Urol 2012; 187 (4S): e724
  • 18
    Kenney P, Chapin B, Culp S et al. Does cytoreductive nephrectomy improve survival in non-clear cell renal cell carcinoma. J Urol 2012; 187 (4S): e727
  • 19
    Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002; 20: 23762381
  • 20
    Waldert M, Haitel A, Marberger M et al. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC. BJU Int 2008; 102: 13811384
  • 21
    Schutz FA, Je Y, Richards CJ, Choueiri TK. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol 2012; 30: 871877
  • 22
    Choueiri TK, Plantade A, Elson P et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008; 26: 127131
  • 23
    Heng DY, Xie W, Regan MM et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27: 57945799
  • 24
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373383
  • 25
    Filson CP, Redman BG, Dunn RL, Miller DC. Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma. Urology 2011; 77: 825830.e1
  • 26
    Shuch B, Said J, La Rochelle JC et al. Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology–is up-front resection indicated and, if not, is it avoidable? J Urol 2009; 182: 21642171
  • 27
    Zini L, Capitanio U, Perrotte P et al. Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. Urology 2009; 73: 342346
  • 28
    You D, Jeong IG, Ahn JH et al. The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy. J Urol 2011; 185: 5459
  • 29
    Aben KK, Heskamp S, Janssen-Heijnen ML et al. Better survival in patients with metastasised kidney cancer after nephrectomy: a population-based study in the Netherlands. Eur J Cancer 2011; 47: 20232032